PTCL, NOS: An update on classification, risk-stratification, and treatment

Jonathan Weiss; John Reneau; Ryan A. Wilcox

doi:10.3389/fonc.2023.1101441

Frontiers in Oncology (Feb 2023)

PTCL, NOS: An update on classification, risk-stratification, and treatment

Jonathan Weiss,
John Reneau,
Ryan A. Wilcox

Affiliations

Jonathan Weiss: Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, United States
John Reneau: Department of Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States
Ryan A. Wilcox: Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, United States

DOI: https://doi.org/10.3389/fonc.2023.1101441
Journal volume & issue: Vol. 13

Abstract

Read online

The peripheral T-cell lymphomas (PTCL) are relatively rare, heterogeneous, and therapeutically challenging. While significant therapeutic gains and improved understanding of disease pathogenesis have been realized for selected PTCL subtypes, the most common PTCL in North America remains “not otherwise specified (NOS)” and is an unmet need. However, improved understanding of the genetic landscape and ontogeny for the PTCL subtypes currently classified as PTCL, NOS have been realized, and have significant therapeutic implications, which will be reviewed here.

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal

Abstract

Keywords